Giannoni et al. (76) demonstrated that prostate carcinoma-derived interleukin-6 (IL6) activates CAFs, which in turn secrete MMPs, leading prostate cancer (PCa) cells to acquire EMT phenotype and to develop metastases in vivo (76). Here, IL6 is linked to posterior cortical atrophy.